Loading
Tests that measure a set of genes in a removed tumour to estimate how likely it is to come back, so patients with low scores can safely skip chemotherapy.
Multigene expression assays run on resected tumour tissue estimate recurrence risk and, for some, chemotherapy benefit. Oncotype DX (21 genes) and MammaPrint (70 genes) are the best known in breast cancer, where the TAILORx and MINDACT trials showed that most women with low scores gain nothing from chemotherapy; Prolaris and Decipher serve the same purpose in prostate cancer. They are recommended in major guidelines and reimbursed in many systems.
RNA is extracted from fixed tumour tissue and the expression of a fixed gene panel is measured by RT-PCR or microarray and combined into a validated risk score.
A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.
A 21-gene test that tells most women with early hormone-positive breast cancer whether they can safely skip chemotherapy.
A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.
Query for this technology: (TITLE:"Gene-expression prognostic assays" OR ABSTRACT:"Gene-expression prognostic assays") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gene-expression prognostic assays, not a curated reading list.
Shares MammaPrint (70-gene signature), RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), Oncotype DX, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares Oncotype DX, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares Prolaris, RNA sequencing & expression profiling, Prostate cancer.
Shares Prolaris, RNA sequencing & expression profiling, Prostate cancer.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
A Bioconductor package implementing the published breast cancer molecular subtype and prognostic gene signatures, including PAM50.
Classifies muscle-invasive bladder cancer into the six consensus molecular subtypes from expression data.
Consensus molecular subtype classification of colorectal cancer that works on pre-clinical models and biopsies.
The Winton Centre's public tool that estimates how breast cancer treatments after surgery change survival, for patients and clinicians; the web tool's source is published.